Συναλλαγές Prothena Corp PLC - PRTA CFD

Prothena Corporation plc (NASDAQ: PRTA) is a late-stage biotech company focused on developing therapies for neurodegenerative diseases including Alzheimer’s, Parkinson’s, and amyloidosis. With multiple clinical programs and strategic collaborations with Roche, Novo Nordisk, and Bristol Myers Squibb, Prothena is advancing antibody-based treatments with disease-modifying potential. It offers investors targeted exposure to neuroscience innovation and strategic biopharma partnerships.